Sera Prognostics (Nasdaq:SERA) - Aandelenkoers, Nieuws & Analyse

SERA Overzicht aandelen

SERA fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 125.34% per jaar groeien

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $94K )

De winst zal naar verwachting de komende drie jaar met gemiddeld 4.5% per jaar dalen.

Aandeelhouders zijn het afgelopen jaar verwaterd

Aanzienlijke insider-verkoop in de afgelopen 3 maanden

+ 2 meer risico's

Sera Prognostics, Inc. Concurrenten

TScan Therapeutics

NasdaqGM:TCRX

US$255.4m

aTyr Pharma

NasdaqCM:ATYR

US$261.9m

2seventy bio

NasdaqGS:TSVT

US$193.5m

Inhibrx Biosciences

NasdaqGS:INBX

US$215.1m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Sera Prognostics
Historische aandelenkoersen
Huidige aandelenkoers	US$6.44
52 Week Hoogtepunt	US$12.36
52 Week Laag	US$1.81
Bèta	1.04
11 maand verandering	-7.47%
3 maanden verandering	-4.45%
1 Jaar Verandering	223.62%
33 jaar verandering	-39.25%
5 jaar verandering	n/a
Verandering sinds IPO	-45.88%

Recent nieuws en updates

We're Not Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn

Jul 19

Recent updates

Is Sera Prognostics (NASDAQ:SERA) In A Good Position To Deliver On Growth Plans?

Oct 03

We Think Sera Prognostics (NASDAQ:SERA) Can Afford To Drive Business Growth

Jun 15

We're Keeping An Eye On Sera Prognostics' (NASDAQ:SERA) Cash Burn Rate

Feb 16

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Nov 03

A Negative EV Opportunity - Sera Prognostics Has A Chance To Become Standard Of Care In Preterm Birth Risk Screening

Aug 10

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Jul 21

Here's Why We're Not Too Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Situation

Apr 06

We're Hopeful That Sera Prognostics (NASDAQ:SERA) Will Use Its Cash Wisely

Dec 15

Rendement voor aandeelhouders

	SERA	US Biotechs	US Markt
7D	4.2%	4.0%	2.0%
1Y	223.6%	18.0%	32.4%

Rendement versus industrie: SERA overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 18 % opleverde.

Rendement versus markt: SERA overtrof de US markt, die het afgelopen jaar een rendement opleverde van 32.4 %.

Prijsvolatiliteit

Is SERA's price volatile compared to industry and market?
SERA volatility
SERA Average Weekly Movement	11.7%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van SERA is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van SERA is het afgelopen jaar gedaald van 26% naar 12%, maar is nog steeds hoger dan 75% van de US -aandelen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2008	56	Zhenya Lindgardt	seraprognostics.com

Sera Prognostics, Inc., een diagnostisch bedrijf voor de gezondheid van vrouwen, ontdekt, ontwikkelt en verkoopt biomarkertests voor het verbeteren van zwangerschapsuitkomsten in de Verenigde Staten. Het bedrijf ontwikkelt de PreTRM-test, een op bloed gebaseerde biomarkertest om het risico op spontane vroeggeboorte in enkelvoudige zwangerschappen te voorspellen. Het bedrijf ontwikkelt ook een portfolio van productkandidaten voor verschillende zwangerschapsgerelateerde aandoeningen, waaronder vroeggeboorte, pre-eclampsie, moleculaire time-to-birth, predictive analytics, zwangerschapsdiabetes mellitus, foetale groeibeperking, doodgeboorte en postnatale depressie.

Sera Prognostics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Sera Prognostics zich tot de beurswaarde?
SERA fundamentele statistieken
Marktkapitalisatie	US$215.47m
Inkomsten(TTM)	-US$32.24m
Inkomsten(TTM)	US$94.00k

2,314x

P/S-verhouding

-6.7x

Koers/Winstverhouding

Is SERA overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SERA resultatenrekening (TTM)
Inkomsten	US$94.00k
Kosten van inkomsten	US$74.00k
Brutowinst	US$20.00k
Overige uitgaven	US$32.26m
Inkomsten	-US$32.24m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.95
Brutomarge	21.28%
Nettowinstmarge	-34,302.13%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde SERA op de lange termijn?

Bekijk historische prestaties en vergelijking

SERA Overzicht aandelen

Beloningen

Risicoanalyse

Sera Prognostics, Inc. Concurrenten

NasdaqGM:TCRX

US$255.4m

NasdaqCM:ATYR

US$261.9m

NasdaqGS:TSVT

US$193.5m

NasdaqGS:INBX

US$215.1m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Sera Prognostics, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Sera Prognostics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Sera Prognostics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

We're Not Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn

Sera Prognostics Inc. Announces Publication of Positive AVERT Trial Results in the International Peer-Reviewed Journal, Diagnostics

Chief Data Officer recently sold US$86k worth of stock

Recent updates

Sera Prognostics, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Sera Prognostics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Sera Prognostics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

We're Not Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn

Sera Prognostics Inc. Announces Publication of Positive AVERT Trial Results in the International Peer-Reviewed Journal, Diagnostics

Chief Data Officer recently sold US$86k worth of stock

First quarter 2024 earnings released: US$0.25 loss per share (vs US$0.34 loss in 1Q 2023)

Sera Prognostics, Inc. to Report Q1, 2024 Results on May 08, 2024

Sera Prognostics, Inc., Annual General Meeting, Jun 06, 2024

Chief Scientific Officer notifies of intention to sell stock

President recently sold US$364k worth of stock

Sera Prognostics' PreTRM: A Speculative Buy In Women's Health

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

No longer forecast to breakeven

Sera Prognostics, Inc. to Report Q4, 2023 Results on Mar 20, 2024

President recently sold US$225k worth of stock

Sera Prognostics: The Pregnancy Company On A Hot Streak

Independent Chairman notifies of intention to sell stock

General Counsel recently sold US$52k worth of stock

New major risk - Share price stability

Sera Prognostics Inc. Announces Preliminary Efficacy Met in Pivotal Prime Study Interim Look - Enrollment to Stop Due to Success

Consensus revenue estimates decrease by 14%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sera Prognostics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Is Sera Prognostics (NASDAQ:SERA) In A Good Position To Deliver On Growth Plans?

Consensus revenue estimates decrease by 55%, EPS upgraded

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Sera Prognostics, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Market cap size

We Think Sera Prognostics (NASDAQ:SERA) Can Afford To Drive Business Growth

Sera Prognostics, Inc. Announces Resignation of Nadia Altomare from the Position of Chief Commercial Officer of the Company, Effective as of June 9, 2023

Sera Prognostics, Inc. Announces Board Changes

First quarter 2023 earnings: EPS exceeds analyst expectations

Full year 2022 earnings: Revenues miss analyst expectations

Sera Prognostics, Inc. Announces Positive Top-Line Data from AVERT PRETERM TRIAL

We're Keeping An Eye On Sera Prognostics' (NASDAQ:SERA) Cash Burn Rate

Sera Prognostics, Inc. Announces Publication of Data Predicting Clinical Utility and Cost Effectiveness of the Pretrm® Test-And-Treat Strategy Across Diverse Populations

Insufficient new directors

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Sera Prognostics, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Price target decreased to US$7.00

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

A Negative EV Opportunity - Sera Prognostics Has A Chance To Become Standard Of Care In Preterm Birth Risk Screening

Sera Prognostics, Inc. to Report Q2, 2022 Results on Aug 10, 2022

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

Chief Scientific Officer notifies of intention to sell stock

Sera Prognostics Appoints Jane Barlow to Nominating and Governance Committee

Sera Prognostics, Inc.(NasdaqGM:SERA) dropped from Russell 2500 Value Index

Sera Prognostics, Inc. Announces Publication of Data Demonstrating Improved Performance of its PreTRM Test with More Precise Gestational Age

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Sera Prognostics, Inc. to Report Q1, 2022 Results on May 10, 2022

Insufficient new directors

Sera Prognostics, Inc., Annual General Meeting, Jun 03, 2022

Sera Prognostics, Inc Appoints Jane F. Barlow as Director to the Board to Serve as Class I Director

Here's Why We're Not Too Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Situation

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind